Clinical trials: Hormone Refractory
Prostate Cancer
Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00242931
- Testing
- Nonmyeloablative stem cell conditioning regimen
- Sponsor
- OHSU Knight Cancer Institute
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors…
- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
- Trial name
- Luca-1 (NCT07705334)
- Testing
- SHY-ONC6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- SHY Therapeutics
Metastatic Breast Cancer
Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer
This study of hormone positive (estrogen receptor [ER]), metastatic invasive ductal breast cancer looks at functional scanning using positron emission tomography (PET) and patient response to hormone therapy.
- Trial name
- NCT00358098
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer, Solid Tumors
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2).
- Trial name
- NCT05262400
- Testing
- PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 235 people
- Sponsor
- Pfizer
Prostatic Neoplasms
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
- Trial name
- NCT00036556
- Testing
- Atrasentan
- Where
- 234 sites in United States, Australia and 15 more
- Volunteers
- 941 people
- Sponsor
- Abbott
Prostate Cancer
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic…
- Trial name
- NCT00003626
- Testing
- dolastatin 10
- Where
- 3 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Hormone Refractory Prostate Cancer
RNActive®-Derived Therapeutic Vaccine
This is a Phase I/IIa open, uncontrolled, prospective study, to be conducted in an out-patient setting. The present study is one of two clinical trials of the RNActive®-derived vaccine CV9103 being conducted concurrently in the…
- Trial name
- NCT00906243
- Testing
- CV9103
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Prostate Cancer
Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
The purpose of this trial is to confirm a safe dose of AS1404, to be given with docetaxel, and to see whether adding AS1404 and docetaxel together improves the outcome of the treatment, when compared to docetaxel alone.
- Trial name
- NCT00111618
- Testing
- AS1404 (DMXAA)
- Where
- 27 sites in United States
- Volunteers
- 70 people
- Sponsor
- Antisoma Research
Prostate Carcinoma Metastatic to the Bone
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
This is an open label study designed to examine the effects of Enzalutamide with concurrent administration of Radium Ra 223 dichloride in Castrate-Resistant (Hormone-Refractory) Prostate Cancer subjects with symptomatic bone…
- Trial name
- NCT02507570
- Testing
- Enzalutamide, Radium ra 223 dichloride
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Carolina Research Professionals, LLC
Hormone Refractory Prostate Cancer
Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer
This investigational study involves treatment with an Ad/PSA vaccine for men with prostate cancer who present with evidence of hormone refractory metastatic disease.
- Trial name
- APP22 (NCT00583024)
- Testing
- ADENOVIRUS/PSA VACCINE
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- David M Lubaroff
Prostate Cancer
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than once drug may kill more tumor cells.
- Trial name
- NCT00003717
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- St. Barnabas Medical Center
Prostate Cancer
Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients
The purpose of this study is to better understand a new type of radiology test called positron emission tomography (PET) with carbon 11 methionine to determine which patients have a beneficial effect from anti-cancer therapy with…
- Trial name
- NCT00139204
- Testing
- C11 Methionine PET scan
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
This study was a multi-center, randomized, double-blind, placebo controlled Phase III study to determine the efficacy and safety of treatment with buparlisib plus fulvestrant versus fulvestrant plus placebo in postmenopausal…
- Trial name
- BELLE-2 (NCT01610284)
- Testing
- Fulvestrant, BKM120
- Where
- 268 sites in United States, Argentina and 27 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals
Estrogen Receptor Negative, HER2/Neu Negative
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
The purpose of this study is to see whether a combination of two different drugs - pembrolizumab and capecitabine - is safe, and if it might be effective in treating triple negative and hormone-refractory breast cancer.
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma
- Trial name
- NCT03044730
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Prostate Cancer
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
BAY 43-9006 (Sorafenib) is an experimental cancer drug produced by Bayer Health Care Corporation. It represents a new class of anticancer agents known as bi-aryl ureas.
- Trial name
- NCT00090545
- Testing
- BAY 43-9006
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying the effectiveness of sorafenib in treating patients who have metastatic or…
- Trial name
- NCT00093457
- Testing
- sorafenib tosylate
- Where
- 7 sites in Canada
- Volunteers
- 28 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher…
- Trial name
- NCT00003400
- Testing
- filgrastim, carmustine, cisplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Maryland, Baltimore
Sinusitis
Establishment of Precise Diagnosis and Treatment System for Refractory Chronic Rhinosinusitis
Chronic rhinosinusitis that recurs after adequate surgery and conventional medical treatment is called refractory chronic rhinosinusitis (RCRS).
- Trial name
- NCT05390255
- Testing
- Mometasone furoate nasal spray hormone, Mometasone furoate nasal spray hormone + oral hormone, Mometasone furoate nasal spray hormone + omalizumab
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Beijing Tongren Hospital
Prostate Cancer
GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer
Prostate cancer is one of the most common malignancies affecting men all over the World. Metastatic prostate cancer responds to androgen deprivation for a variable period (20-25 months).
- Trial name
- NCT01487720
- Testing
- GEMOX
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Asan Medical Center
Prostate Cancer
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004071
- Testing
- leflunomide, mitoxantrone hydrochloride, prednisone
- Where
- 3 sites in United States
- Sponsor
- Pfizer